AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19933961 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management (CM) program led by nurses and dietitians
Number of subjects: 419
Study 19933961 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management (CM) program
Number of subjects: 419
Study 19933961 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 419
Study 17314577 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg M6G
Number of subjects: 41
Study 17314577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15543797 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized nipple detection method
Number of subjects: 744
Study 11453311 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg moxifloxacin once daily for 10 days
Number of subjects: 229
Study 11453311 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin once daily for 10 days
Number of subjects: 229
Study 11453311 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 229
Study 9656942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh rule
Number of subjects: 934
Study 9656942 — intervention group
Group type: COMPARATOR
Intervention: Ottawa rule
Number of subjects: 934
Study 8092599 — intervention group
Group type: COMPARATOR
Intervention: 0 mL/kg magnesium citrate
Number of subjects: 64
Study 8092599 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL/kg magnesium citrate
Number of subjects: 64
Study 8092599 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mL/kg magnesium citrate
Number of subjects: 64
Study 8092599 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mL/kg magnesium citrate
Number of subjects: 64
Study 3337929 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg/day
Number of subjects: 18
Study 3337929 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg/day
Number of subjects: 18
Study 3337929 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1500 mg/day
Number of subjects: 18
Study 29150968 — intervention group
Group type: EXPERIMENTAL
Intervention: 453 nm blue light irradiation for 30 minutes after skin perturbation
Number of subjects: 22
Study 29150968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no light administered)
Number of subjects: 22
Study 28277990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxygenated fatty acids (HOFA)
Number of subjects: 152
Study 26032041 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 63
Study 26032041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 24127200 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen submicron particle capsules 200 mg
Number of subjects: 254
Study 24127200 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen tablets 250 mg
Number of subjects: 254
Study 24127200 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen submicron particle capsules 400 mg
Number of subjects: 254
Study 24127200 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen tablets 500 mg
Number of subjects: 254
Study 24127200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 20805762 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated pins
Number of subjects: 40
Study 20805762 — intervention group
Group type: COMPARATOR
Intervention: Titanium-alloy pins
Number of subjects: 40
Study 20805762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 18080339 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg daily
Number of subjects: 332
Study 18080339 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily
Number of subjects: 332
Study 16538941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitigator Sting and Bite Treatment
Number of subjects: 24
Study 16538941 — intervention group
Group type: COMPARATOR
Intervention: Calamine lotion
Number of subjects: 24
Study 12683506 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub
Number of subjects: 0
Study 12683506 — intervention group
Group type: COMPARATOR
Intervention: Soap and water (control)
Number of subjects: 0
Study 11113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of propafenone (450 to 675 mg/day)
Number of subjects: 60
Study 11113407 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of propafenone with low-dose quinidine (150 mg/day)
Number of subjects: 60
Study 11113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of propafenone plus quinidine (600 mg/day)
Number of subjects: 60
Study 11113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (combination of all treatments)
Number of subjects: 60
Study 11113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 60
Study 11113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled AF
Number of subjects: 60
Study 9082591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular laser therapy
Number of subjects: 129
Study 9082591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 129
Study 1487096 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling‐based aural rehabilitation program with hearing aids
Number of subjects: 31
Study 1487096 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids only
Number of subjects: 31
Study 1487096 — intervention group
Group type: COMPARATOR
Intervention: Neither hearing aids nor counseling‐based AR
Number of subjects: 31
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 25 mg plus scopolamine 0.4 mg with d-amphetamine 10 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine 1 mg with d-amphetamine 10 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: COMPARATOR
Intervention: scopolamine 0.25 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: COMPARATOR
Intervention: scopolamine 0.5 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: COMPARATOR
Intervention: scopolamine 0.6 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: COMPARATOR
Intervention: marezine 50 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: COMPARATOR
Intervention: meclizine 50 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: COMPARATOR
Intervention: dimenhydrinate 50 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: COMPARATOR
Intervention: scopolamine 1 mg with d-amphetamine 5 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: COMPARATOR
Intervention: promethazine 25 mg with d-amphetamine 10 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine 1 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine 0.8 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 25 mg oral
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 25 mg I.M.
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 25 mg with scopolamine 0.4 mg
Number of subjects: 0
Study 3888169 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 25 mg oral plus 25 mg I.M. with d-amphetamine 10 mg
Number of subjects: 0
Study 30676814 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% glucose (GLU)
Number of subjects: 10
Study 30676814 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% maltose (MAL)
Number of subjects: 10
Study 30676814 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin (MDX)
Number of subjects: 10
Study 30676814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 29112459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine + Parent Training (PT)
Number of subjects: 128
Study 29112459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine alone
Number of subjects: 128
Study 29112459 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT) alone
Number of subjects: 128
Study 29112459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) alone
Number of subjects: 128
Study 27761693 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa extract
Number of subjects: 160
Study 27761693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 24943480 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP) 100 mg
Number of subjects: 30
Study 24943480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22768457 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin therapy
Number of subjects: 104
Study 22768457 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian electrocauterization
Number of subjects: 104
Study 20880898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined β blocker and behavioural migraine management
Number of subjects: 232
Study 20880898 — intervention group
Group type: EXPERIMENTAL
Intervention: β blocker alone
Number of subjects: 232
Study 20880898 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural migraine management alone
Number of subjects: 232
Study 20880898 — intervention group
Group type: COMPARATOR
Intervention: Optimised acute treatment alone
Number of subjects: 232
Study 20880898 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised acute treatment plus combined β blocker and behavioural migraine management
Number of subjects: 232
Study 17581292 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6MW)
Number of subjects: 23
Study 17581292 — intervention group
Group type: EXPERIMENTAL
Intervention: shuttle walking test (SWT)
Number of subjects: 23
Study 15530671 — intervention group
Group type: EXPERIMENTAL
Intervention: PncCRM vaccine
Number of subjects: 115
Study 15530671 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (hepatitis B)
Number of subjects: 115
Study 11255809 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomycin D (one course administered within one week after evacuation of molar tissues)
Number of subjects: 60
Study 11255809 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous fluid and analgesic drugs only)
Number of subjects: 60
Study 9825577 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-C (ProME(Epidoxorubicin)CE‐CytaBOM)
Number of subjects: 250
Study 9825577 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-C (ProMI(Idarubicin)CE‐CytaBOM)
Number of subjects: 250
Study 9825577 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-C
Number of subjects: 250
Study 9825577 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-C
Number of subjects: 250
Study 9825577 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy (after achieving complete remission)
Number of subjects: 250
Study 9825577 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further therapy after complete remission)
Number of subjects: 250
Study 9825577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal toxicities
Number of subjects: 250
Study 7647347 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-social family intervention based on Expressed Emotion (EE)
Number of subjects: 0
Study 7647347 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2469953 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfomucopolysaccharide
Number of subjects: 30
Study 2469953 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 333506 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque
Number of subjects: 39
Study 333506 — intervention group
Group type: COMPARATOR
Intervention: Isopaque Coronar
Number of subjects: 39
Study 31841780 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led Body Project
Number of subjects: 680
Study 31841780 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led Body Project
Number of subjects: 680
Study 31841780 — intervention group
Group type: EXPERIMENTAL
Intervention: eBody Project
Number of subjects: 680
Study 31841780 — intervention group
Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 680
Study 28277423 — intervention group
Group type: EXPERIMENTAL
Intervention: In-water training program with increased resistance (water parachute)
Number of subjects: 12
Study 28277423 — intervention group
Group type: COMPARATOR
Intervention: Control group (same training without parachute)
Number of subjects: 12
Study 29510398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Diacetylmorphine (DAM)
Number of subjects: 28
Study 29510398 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 28
Study 26086587 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 0
Study 23600965 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 120
Study 23600965 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 120
Study 23600965 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (physiotherapy + acupuncture)
Number of subjects: 120
Study 22005660 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 15 mL of 0.25% bupivacaine
Number of subjects: 12
Study 22005660 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 19858328 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning intervention including action and coping plans with two booster sessions
Number of subjects: 182
Study 19858328 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 182
Study 15703510 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 8725
Study 15703510 — intervention group
Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 8725
Study 11908844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepressed participants
Number of subjects: 0
Study 11908844 — intervention group
Group type: COMPARATOR
Intervention: Subclinically depressed participants
Number of subjects: 0
Study 10431945 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal vascular test (TVT)
Number of subjects: 199
Study 7473523 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care
Number of subjects: 554
Study 7473523 — intervention group
Group type: COMPARATOR
Intervention: Outpatient clinic (control)
Number of subjects: 554
Study 7473523 — intervention group
Group type: COMPARATOR
Intervention: Nurse-practitioner clinic (control)
Number of subjects: 554
Study 2246657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (maximal dose 24 mg/day)
Number of subjects: 7
Study 2246657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (administered for a minimum of six months at optimal dose)
Number of subjects: 7
Study 2246657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine therapy
Number of subjects: 7
Study 7394143 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention group (received repeated reminders of risk and procedures for cessation of smoking, reduction of blood pressure, and dietary alteration to lower serum cholesterol)
Number of subjects: 575
Study 7394143 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention group
Number of subjects: 575
Study 7394143 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group (received usual medical care as they saw fit)
Number of subjects: 575
Study 7394143 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 575
Study 31479159 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor treatment
Number of subjects: 63
Study 31479159 — intervention group
Group type: EXPERIMENTAL
Intervention: POLE-mutated CRCs
Number of subjects: 63
Study 31479159 — intervention group
Group type: EXPERIMENTAL
Intervention: POLE status assessment
Number of subjects: 63
Study 30784638 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case finding strategy (combination of active and passive case finding)
Number of subjects: 25677
Study 30784638 — intervention group
Group type: COMPARATOR
Intervention: Usual care (passive case finding)
Number of subjects: 25677
Study 24754313 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprotirome 100 μg day(-1)
Number of subjects: 98
Study 24754313 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprotirome 200 μg day(-1)
Number of subjects: 98
Study 24754313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 23891459 — intervention group
Group type: EXPERIMENTAL
Intervention: Group motivational interviewing intervention (Free Talk)
Number of subjects: 193
Study 23891459 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 193
Study 21312304 — intervention group
Group type: EXPERIMENTAL
Intervention: Testofen (600 mg per day)
Number of subjects: 60
Study 21312304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21312304 — intervention group
Group type: EXPERIMENTAL
Intervention: Testofen
Number of subjects: 60
Study 19406557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (two doses of 200mg iron sucrose)
Number of subjects: 260
Study 19406557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (three doses of 200mg iron sucrose)
Number of subjects: 260
Study 19406557 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (daily 80 mg ferrous sulphate)
Number of subjects: 260
Study 17579165 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided core needle biopsy
Number of subjects: 0
Study 15015443 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM)
Number of subjects: 106
Study 15015443 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin
Number of subjects: 106
Study 15015443 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 106
Study 12899196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stress participants
Number of subjects: 0
Study 12899196 — intervention group
Group type: COMPARATOR
Intervention: Low-stress participants
Number of subjects: 0
Study 9549575 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1.2 g daily in 3 divided doses from 2 days before to 14 days after surgery
Number of subjects: 150
Study 9549575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight dextran 500 ml, infused intravenously at 50 ml/hour during surgery and on each of the following 2 days
Number of subjects: 150
Study 9549575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 150
Study 8056005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (specific dosage not mentioned)
Number of subjects: 348
Study 2494249 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray, 400 micrograms daily
Number of subjects: 90
Study 2494249 — intervention group
Group type: COMPARATOR
Intervention: Astemizole, 10 mg daily
Number of subjects: 90
Study 2494249 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone plus astemizole
Number of subjects: 90
Study 2494249 — intervention group
Group type: COMPARATOR
Intervention: Astemizole alone
Number of subjects: 90
Study 2494249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trial medications (beclomethasone and astemizole)
Number of subjects: 90
Study 29912983 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg fast-release melatonin
Number of subjects: 116
Study 29912983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 28731485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) in the continuous blood purification (CBP) group, n = 11
Number of subjects: 48
Study 28731485 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional comprehensive treatment plus high-volume hemofiltration (CBP group)
Number of subjects: 48
Study 28731485 — intervention group
Group type: COMPARATOR
Intervention: Conventional comprehensive treatment only (non-CBP group), n = 11
Number of subjects: 48
Study 28731485 — intervention group
Group type: COMPARATOR
Intervention: Baseline Th17%, Treg%, Th17/Treg, IL‐6, IL‐17, IL‐23, IL‐10 and TGF‐β1 in non-survival group
Number of subjects: 48
Study 28731485 — intervention group
Group type: EXPERIMENTAL
Intervention: Th17% and Th17/Treg
Number of subjects: 48
Study 26044463 — intervention group
Group type: EXPERIMENTAL
Intervention: FAmily CEntered advance care planning intervention (two face-to-face sessions with a trained facilitator: Session 1: Disease-Specific Advance Care Planning Respecting Choices Interview; Session 2: Completion of advance directive)
Number of subjects: 288
Study 26044463 — intervention group
Group type: COMPARATOR
Intervention: Healthy Living Control (two sessions: Session 1: Developmental/Relationship History; Session 2: Nutrition)
Number of subjects: 288
Study 22171668 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tapping implants placed after bone condensing
Number of subjects: 102
Study 22171668 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-self-tapping implants placed after bone condensing
Number of subjects: 102
Study 22171668 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tapping implants placed after bone drilling
Number of subjects: 102
Study 22171668 — intervention group
Group type: COMPARATOR
Intervention: Non-self-tapping implants placed after bone drilling
Number of subjects: 102
Study 22171668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant types placed after bone condensing
Number of subjects: 102
Study 22171668 — intervention group
Group type: COMPARATOR
Intervention: Both implant types placed after bone drilling
Number of subjects: 102
Study 20873697 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine ophthalmic solution
Number of subjects: 47
Study 20873697 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study 18566549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized Japanese cedar extract, administered daily to once a week after six weeks.
Number of subjects: 61